多发性硬化症中的微生物群；我们所处的位置、已知与未知
Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know.
作者信息
Boziki Marina Kleopatra, Kesidou Evangelia, Theotokis Paschalis, Mentis Alexios-Fotios A, Karafoulidou Eleni, Melnikov Mikhail, Sviridova Anastasia, Rogovski Vladimir, Boyko Alexey, Grigoriadis Nikolaos
机构信息
2nd Neurological University Department, Aristotle University of Thessaloniki, AHEPA General Hospital, 54634 Thessaloniki, Greece.
Public Health Laboratories, Hellenic Pasteur Institute, Athens 11521, Greece.
出版信息
Brain Sci. 2020 Apr 14;10(4):234. doi: 10.3390/brainsci10040234.
Abstract
An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut-brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated.
摘要
据报道，在过去十年中，多发性硬化症（MS）的发病率有所上升，这可能与环境因素有关。这篇综述文章旨在总结目前针对肠脑轴研究的进展，肠脑轴介导中枢神经系统与肠道微生物群之间的通讯。同时，也概述了许多研究的临床数据，这些研究评估了给予MS患者疾病修正治疗对肠道微生物群的影响。
相似文献
1
Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know.多发性硬化症中的微生物群；我们所处的位置、已知与未知
Brain Sci. 2020 Apr 14;10(4):234. doi: 10.3390/brainsci10040234.
2
Serotonin: A mediator of the gut-brain axis in multiple sclerosis.血清素：多发性硬化症中肠道-大脑轴的中介。
Mult Scler. 2018 Aug;24(9):1144-1150. doi: 10.1177/1352458517739975. Epub 2017 Nov 9.
3
Gut microbiome research in multiple sclerosis.多发性硬化症的肠道微生物组研究。
Neurosci Res. 2021 Jul;168:28-31. doi: 10.1016/j.neures.2021.05.001. Epub 2021 May 11.
4
Modification of the gut microbiome to combat neurodegeneration.肠道微生物组的修饰以对抗神经退行性变。
Rev Neurosci. 2019 Nov 26;30(8):795-805. doi: 10.1515/revneuro-2019-0005.
5
The Emerging Role of the Gut Microbiome in Adult Patients With Multiple Sclerosis.肠道微生物群在成年多发性硬化症患者中的新作用。
J Neurosci Nurs. 2016 Dec;48(6):358-364. doi: 10.1097/JNN.0000000000000252.
6
The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue.多发性硬化症中的肠道微生物群：一条潜在的治疗途径。
Med Sci (Basel). 2018 Aug 24;6(3):69. doi: 10.3390/medsci6030069.
7
A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis.双向关联：肠道微生物群与中枢神经系统疾病在多发性硬化的双相小鼠模型中的关系。
Gut Microbes. 2017 Nov 2;8(6):561-573. doi: 10.1080/19490976.2017.1353843. Epub 2017 Aug 4.
8
Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.关注肠-脑轴：多发性硬化、肠道屏障和微生物组。
World J Gastroenterol. 2018 Oct 7;24(37):4217-4223. doi: 10.3748/wjg.v24.i37.4217.
9
[Gut human microbiota and multiple sclerosis].[肠道人类微生物群与多发性硬化症]
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10. Vyp. 2):11-19. doi: 10.17116/jnevro201711710211-19.
10
Comparison of the Intestinal Microbiome of Italian Patients with Multiple Sclerosis and Their Household Relatives.意大利多发性硬化症患者及其亲属肠道微生物群的比较。
Life (Basel). 2021 Jun 26;11(7):620. doi: 10.3390/life11070620.
引用本文的文献
1
A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individuals.一种益生菌方法通过调节多发性硬化症患者和健康个体的肠道微生物群代谢产物，确定了以调节性T细胞为中心的免疫调节作用。
EBioMedicine. 2025 Jun;116:105743. doi: 10.1016/j.ebiom.2025.105743. Epub 2025 May 12.
2
Plasma and Visceral Organ Kynurenine Metabolites Correlate in the Multiple Sclerosis Cuprizone Animal Model.在多发性硬化症铜螯合剂动物模型中，血浆和内脏器官犬尿氨酸代谢产物存在相关性。
Int J Mol Sci. 2025 Jan 24;26(3):976. doi: 10.3390/ijms26030976.
3
Neurotherapeutic impact of vanillic acid and ibudilast on the cuprizone model of multiple sclerosis.香草酸和异丁司特对多发性硬化症铜螯合剂模型的神经治疗作用
Front Mol Neurosci. 2025 Jan 10;17:1503396. doi: 10.3389/fnmol.2024.1503396. eCollection 2024.
4
Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).关于环境应激源暴露与免疫衰老（ISC）动态变化相关改变以及多发性硬化症（MS）全球发病率上升之间联系的证据综述。
Immun Ageing. 2024 Oct 22;21(1):73. doi: 10.1186/s12979-024-00473-w.
5
Gut microbiota in multiple sclerosis and animal models.多发性硬化症及动物模型中的肠道微生物群
FEBS J. 2025 Mar;292(6):1330-1356. doi: 10.1111/febs.17161. Epub 2024 May 30.
6
The comparative effects of bone marrow mesenchymal stem cells and supernatant transplantation on demyelination and inflammation in cuprizone model.骨髓间充质干细胞及其上清液移植对 CPZ 模型脱髓鞘和炎症的比较影响。
Mol Biol Rep. 2024 May 24;51(1):674. doi: 10.1007/s11033-024-09628-w.
7
The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study.多发性硬化症治疗对肠道微生物群失调的影响：一项纵向前瞻性研究。
Microb Cell. 2024 Apr 4;11:106-115. doi: 10.15698/mic2024.03.819. eCollection 2024.
8
Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study.探究口腔微生物群改变的代谢特征作为多发性硬化症的鉴别因素：一项初步研究。
Sci Rep. 2024 Apr 2;14(1):7786. doi: 10.1038/s41598-024-57949-4.
9
Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.疾病修饰疗法对多发性硬化症肠-脑轴的影响
Medicina (Kaunas). 2023 Dec 20;60(1):6. doi: 10.3390/medicina60010006.
10
Beneficial immune-modulatory effects of the N-163 strain of -produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study.由N-163菌株产生的1,3-1,6β-葡聚糖在杜兴氏肌营养不良症中的有益免疫调节作用：一项开放标签、前瞻性、探索性病例对照临床研究的结果。
IBRO Neurosci Rep. 2023 Jul 4;15:90-99. doi: 10.1016/j.ibneur.2023.06.007. eCollection 2023 Dec.
本文引用的文献
1
The influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosis.干扰素β-1b 对多发性硬化症患者肠道微生物组成的影响。
Neurologia (Engl Ed). 2021 Sep;36(7):495-503. doi: 10.1016/j.nrleng.2020.05.006. Epub 2020 May 31.
2
The multiple sclerosis gut microbiota: A systematic review.多发性硬化症的肠道微生物群：系统评价。
Mult Scler Relat Disord. 2020 Jan;37:101427. doi: 10.1016/j.msard.2019.101427. Epub 2019 Oct 2.
3
Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.俄罗斯队列中的原发性进行性多发性硬化症：与肠道细菌多样性的关系。
BMC Microbiol. 2019 Dec 30;19(1):309. doi: 10.1186/s12866-019-1685-2.
4
Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis.富马酸二甲酯在 Lewis 大鼠实验性自身免疫性神经炎中诱导肠道免疫系统的调节特性。
Front Immunol. 2019 Sep 10;10:2132. doi: 10.3389/fimmu.2019.02132. eCollection 2019.
5
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.在多发性硬化症中与阿仑单抗治疗相关的致死性不良事件。
BMC Res Notes. 2019 Aug 12;12(1):497. doi: 10.1186/s13104-019-4507-6.
6
Interfering with leukocyte trafficking in Crohn's disease.干预克罗恩病中的白细胞迁移。
Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101617. doi: 10.1016/j.bpg.2019.05.004. Epub 2019 May 28.
7
Long-term disability progression of pediatric-onset multiple sclerosis.儿童发病多发性硬化的长期残疾进展。
Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.
8
, A Human Gut Commensal, Is as Potent as COPAXONE® in an Animal Model of Multiple Sclerosis.一株人体肠道共生菌，其效力与多发性硬化症动物模型中的 COPAXONE®相当。
Front Immunol. 2019 Mar 22;10:462. doi: 10.3389/fimmu.2019.00462. eCollection 2019.
9
Disease-modifying therapies alter gut microbial composition in MS.疾病修饰疗法改变多发性硬化症患者的肠道微生物组成。
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 26;6(1):e517. doi: 10.1212/NXI.0000000000000517. eCollection 2019 Jan.
10
Multiple sclerosis registries in Europe - An updated mapping survey.欧洲的多发性硬化症登记处——一项最新的图谱调查。
Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4.
Zotero 插件